NCT05152901 is a Phase 1 clinical trial of EpiPen ®. in Anaphylactic Reaction, sponsored by De Motu Cordis.

Who is sponsoring NCT05152901?

NCT05152901 is sponsored by De Motu Cordis.

What drugs are being tested in NCT05152901?

Interventions in NCT05152901: EpiPen ®., Epinephrine (0.3mg) inhaled, Epinephrine (1.3mg), Epinephrine (4mg).

What condition does NCT05152901 study?

NCT05152901 studies Anaphylactic Reaction.

Is NCT05152901 still recruiting?

NCT05152901 is currently completed. Last updated 24 July 2023.

Last reviewed 2023-07-24 · How we verify

NCT05152901

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Inhaled Epinephrine and Intramuscular Epinephrine Administered to Healthy Adults

Completed Phase 1 Last updated 24 July 2023

What this trial tests

Phase 1 trial testing EpiPen ®. in Anaphylactic Reaction in 23 participants. Completed in 6 June 2022.

Timeline

6 January 2022

Primary endpoint
6 June 2022

6 June 2022

Quick facts

Lead sponsor	De Motu Cordis
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	23
Start date	6 January 2022
Primary completion	6 June 2022
Estimated completion	6 June 2022
Sites	1 location across Australia

Drugs / interventions tested

EpiPen ®. — full drug profile →
Epinephrine (0.3mg) inhaled — full drug profile →
Epinephrine (1.3mg) — full drug profile →
Epinephrine (4mg) — full drug profile →

Conditions studied

Anaphylactic Reaction — all drugs for Anaphylactic Reaction →

Sponsor

De Motu Cordis — full company profile →

Who can join

Adults 18 to 45, any sex, with Anaphylactic Reaction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a study to determine the relative bioavailability of inhaled epinephrine compared with 0.3mg epinephrine administered IM in healthy male and female participants.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other De Motu Cordis trials

Trials by the same sponsor.

NCT06013150 — Study of Inhaled DMC-IH1 and Intramuscular (EpiPen®) Epinephrine in Healthy Male and Female Participants. · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05152901 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by De Motu Cordis
Last refreshed: 24 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05152901.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing